Qiagen (QGEN) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
16 Oct, 2026Executive summary
Q4 net sales were $509M (+2% reported, +1% CER); adjusted diluted EPS was $0.55 CER, above the $0.53 CER outlook, with 8% CER growth in non-COVID products.
FY 2023 sales were $1.97B, meeting CER outlook; non-COVID products grew 8% CER and adjusted diluted EPS of $2.09 CER exceeded the $2.07 CER outlook.
Q4 adjusted operating margin improved to 28.0% from 27.1% YoY; FY adjusted operating margin was 26.9% versus 30.6% in 2022.
Financial highlights
Q4 reported operating income was $110.6M, net income $97.7M and diluted EPS $0.42; adjusted net income was $127.2M and adjusted diluted EPS $0.55.
FY reported operating income was $409.9M, net income $341.3M and diluted EPS $1.48; adjusted operating income was $528.6M, adjusted net income $476.9M and adjusted diluted EPS $2.07.
Q4 adjusted gross margin was 65.7%, down from 67.0% YoY; lower capacity utilization and adverse product mix weighed on margin.
Operating cash flow was $459M and free cash flow $310M in FY 2023, versus $715M and $586M, respectively, in 2022.
Outlook and guidance
FY 2024 net sales expected at least $2.0B CER, representing at least 2% CER growth; non-COVID sales growth is expected to reach a solid mid-single-digit rate in H2.
Adjusted diluted EPS expected at least $2.10 CER; adjusted operating margin projected above 28%, improving at least 1 percentage point YoY while supporting portfolio investment.
Guidance includes ~1 percentage point of COVID-19 sales headwinds from 2023; consumables and related revenues are expected to drive growth, while larger-scale instrument sales remain challenging.
FY 2024 non-operating income faces significant pressure from lower interest income and a higher tax rate; currency is expected neutral for sales and to reduce adjusted EPS by ~$0.01 per share.
Q1 2024 net sales expected at least $455M CER and adjusted diluted EPS at least $0.44 CER; currency impact expected neutral on sales and negative ~$0.01 per share on adjusted EPS.
Latest events from Qiagen
- AI-driven automation, new product launches, and margin expansion drive growth amid strategic review.QGEN
Morgan Stanley 24th Annual Global Healthcare Conference - Automation, new launches, and strategic focus drive growth outlook amid leadership transition.QGEN
2026 Global Healthcare Conference - Q2 2026 sales and EPS exceeded expectations, driven by strong growth in core pillars.QGEN
Q2 2026 - New product launches and strategic review drive growth amid leadership transition and stable funding.QGEN
Leerink Global Healthcare Conference 2026 - 2025 saw robust growth, higher dividends, board renewal, and all AGM proposals adopted.QGEN
AGM 2026 - Q1 2026 delivered 2% sales growth and solid profitability, with FY 2026 outlook reaffirmed.QGEN
Q1 2026 - Drives growth in sample prep with automation, high-value applications, and new tech leadership.QGEN
Status Update - 2028 plan targets ~7% sales CAGR, ≥31% margin, and $1B returns, led by innovation and efficiency.QGEN
CMD 2024 - Exceeded 2024 targets with strong recurring revenue, margin gains, and positive 2025 outlook.QGEN
Q4 2024